CEL-SCI Corp. Receives Approval from North Mississippi Health Services’ Institutional Review Board to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
Date : 09/13/2010 @ 9:45AM Source : Business Wire Stock : CEL-SCI Corporation (CVM)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.